1. Home
  2. CELC vs MAT Comparison

CELC vs MAT Comparison

Compare CELC & MAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Celcuity Inc.

CELC

Celcuity Inc.

N/A

Current Price

$86.82

Market Cap

4.2B

Sector

Health Care

ML Signal

N/A

Logo Mattel Inc.

MAT

Mattel Inc.

N/A

Current Price

$14.89

Market Cap

4.2B

ML Signal

N/A

Company Overview

Basic Information
Metric
CELC
MAT
Founded
2011
1945
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Recreational Games/Products/Toys
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
4.2B
IPO Year
2017
1994

Fundamental Metrics

Financial Performance
Metric
CELC
MAT
Price
$86.82
$14.89
Analyst Decision
Strong Buy
Buy
Analyst Count
9
11
Target Price
$112.56
$20.90
AVG Volume (30 Days)
1.1M
4.3M
Earning Date
05-13-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.14
Revenue
N/A
$5,347,623,000.00
Revenue This Year
N/A
$5.92
Revenue Next Year
$720.19
$5.08
P/E Ratio
N/A
$106.25
Revenue Growth
N/A
N/A
52 Week Low
$44.42
$12.73
52 Week High
$151.02
$22.48

Technical Indicators

Market Signals
Indicator
CELC
MAT
Relative Strength Index (RSI) 45.01 56.01
Support Level $82.48 $14.11
Resistance Level $95.59 $15.33
Average True Range (ATR) 4.57 0.47
MACD 0.54 -0.01
Stochastic Oscillator 58.30 49.32

Price Performance

Historical Comparison
CELC
MAT

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.

About MAT Mattel Inc.

Mattel manufactures and markets toy products that are sold to its wholesale partners and direct to retail customers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, hand-held and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Nearly 60% of its net sales were generated from North America in 2025, with the remainder stemming from international markets.

Share on Social Networks: